Ubiquilin 2 modulates ALS/FTD-linked FUS–RNA complex dynamics and stress granule formation

Elizabeth J. Alexander, Amirhossein Ghanbari Niaki, Tao Zhang, Jaya Sarkar, Yang Liu, Raja Sekhar Nirujoji, Akhilesh Pandey, Sua Myong, and Jiou Wang

*Department of Biochemistry and Molecular Biology, Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD 21205; †Department of Neuroscience, Johns Hopkins University School of Medicine, Baltimore, MD 21205; ‡T. C. Jenkins Department of Biophysics, Johns Hopkins University, Baltimore, MD 21218; and #McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205

Edited by Clifford P. Brangwynne, Princeton University/Howard Hughes Medical Institute, Princeton, NJ, and accepted by Editorial Board Member Brenda A. Schulman October 18, 2018 (received for review July 12, 2018)

The ubiquitin-like protein ubiquilin 2 (UBQLN2) has been genetically and pathologically linked to the neurodegenerative diseases amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD), but its normal cellular functions are not well understood. In a search for UBQLN2-interacting proteins, we found an enrichment of stress granule (SG) components, including ALS/FTD-linked heterogeneous ribonucleoprotein fused in sarcoma (FUS). Through the use of an optimized SG detection method, we observed UBQLN2 and its interactors at SGs. A low complexity, Stil1-like repeat region in UBQLN2 was sufficient for its localization to SGs. Functionally, UBQLN2 negatively regulated SG formation. UBQLN2 increased the dynamics of FUS–RNA interaction and promoted the fluidity of FUS–RNA complexes at a single-molecule level. This solubilizing effect corresponded to a dispersal of FUS liquid droplets in vitro and a suppression of FUS SG formation in cells. ALS-linked mutations in UBQLN2 reduced its association with FUS and impaired its function in regulating FUS–RNA complex dynamics and SG formation. These results reveal a previously unrecognized role for UBQLN2 in regulating the early stages of liquid–liquid phase separation by directly modulating the fluidity of protein–RNA complexes and the dynamics of SG formation.

ALS | FTD | stress granule | ubiquilin 2 | FUS

Quality control and stress response programs are critical to cell survival. Defects in both protein quality control (PQC) and RNA homeostasis during stress are central to the pathogenesis of neurodegenerative diseases, such as amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) (1). ALS, also known as Lou Gehrig’s disease, is the most common adult-onset motor neuron disease, and is characterized by progressive loss of both upper and lower motor neurons, while FTD is the second most common type of dementia for people younger than 65 y of age, and is characterized by progressive changes in personality, behavior, and language ability (2, 3). The occurrence of ALS and FTD disease symptoms in up to 50% of cases suggests that ALS and FTD are part of a continuous clinical spectrum (ALS/FTD) (4). Increasing genetic and pathological evidence points to dysregulation of both protein and RNA homeostasis as two major processes underlying these diseases, but the interrelated functions of the molecular players are unclear (1).

The convergence of protein and RNA homeostasis in ALS/FTD pathogenesis suggests that common molecular players exist between the two pathways. ALS and FTD are genetically linked to both PQC factors in the proteasome and autophagy pathways, such as UBQLN2, SQSTM1, optineurin, and VCP, and to RNA binding proteins (RBPs), such as fused in sarcoma (FUS), TAR-DNA binding protein (TDP-43), Ewing sarcoma protein (EWS), TAT binding protein-associated factor 15 (TAF15), heterogeneous ribonucleoprotein A1 (hnRNPA1), and hnRNPA2/B1 (1). RBPs are a hallmark component of proteinaceous inclusions in patients who have ALS/FTD, suggesting that RBP solubility is compromised in patient cells. For example, the RBP FUS is common in inclusions in a large subset of patients with ALS/FTD (5). Over 40 mutations in FUS have been linked to ALS/FTD cases, including some of the most aggressive, juvenile-onset forms of the disease, in both familial and sporadic patients (6, 7). At the cellular level, FUS is involved in the maintenance of genomic integrity, transcription, pre-mRNA splicing, and micro-RNA regulation (8). It contains two amino-terminal intrinsically disordered regions that allow it to form biologically functional complexes in the cell, but also make it prone to aggregate. How FUS solubility is maintained in the cell and how FUS functions in ALS/FTD pathology are still unclear.

The formation of RNP granules by RBPs may be a critical aspect of PQC and RNA homeostasis in ALS/FTD disease pathogenesis (9, 10). Stress granules (SGs) are one type of RNP granule that forms during stress. Stresses such as heat and oxidative and osmotic stresses that trigger protein misfolding and stalled translation all induce the formation of SGs. Stalled translation initiation complexes, along with apoptotic factors, are sequestered in SGs until the stress subsides or the cell adapts to the conditions (11). Oligomerization of low-complexity, intrinsically disordered regions in RBPs bound to RNA drives SG

Significance

Amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) are two devastating neurodegenerative diseases for which there are few treatments. ALS/FTD has been genetically and pathologically linked to both protein quality control (PQC) factors and RNA homeostasis, but the molecular players that bridge these pathways are not well characterized. Here, we identify a role for the ALS/FTD-linked PQC protein ubiquilin 2 (UBQLN2) in maintaining the solubility of RNA binding protein FUS in response to stress. UBQLN2 increases the dynamics of FUS–RNA complex formation, resulting in the negative regulation of stress granule (SG) formation. Because SGs potentially seed toxic inclusions of patients with ALS/FTD, these findings have implications for understanding ALS/FTD pathogenesis and designing new treatments for these diseases.


The authors declare no conflict of interest.

This article is a PNAS Direct Submission. C.P.B. is a guest editor invited by the Editorial Board. Published under the PNAS license.

This article contains supporting information online at www.pnas.org/lookup/suppl/doi:10.1073/pnas.1811997115/-/DCSupplemental.

Published online November 15, 2018.
formation in a process recently recognized as a liquid–liquid phase separation (LLPS) (12–15). This LLPS is tuned by both RNA length and structure. The dynamics of RBP-RNA binding determine RBP fate (16–18). Conversion of RBPs from a dynamic reversible liquid state into an irreversible solid state is proposed to be one of the early steps in disease pathogenesis associated with protein aggregation (9, 10). Importantly, the SG core components TIA-1, eIF3A, PABP, and eIF4G have been found in patient inclusions (10, 19). An increasing number of ALS/FTD-associated proteins found in patient inclusions have also been found in SGs, including FUS, TDP-43, C9orf72 protein and its polydupetide repeats, ataxin 2, hnRNPA2/B1, hnRNPA1, SOD1, and profilin 1 (20–28). ALS/FTD-linked mutations in the RBPs FUS and hnRNPA1, which phase-separate into SGs, have also been shown to accelerate the phase transition of these proteins from a dynamic liquid state to a solid fibril state (14, 15, 27). PQC factors shown to accelerate the phase transition of these proteins from a dynamic reversible liquid state into an irreversible solid state is regulated to maintain RBP solubility during SG assembly. While searching for UBQLN2-interacting proteins through quantitative proteomics, we found an enrichment of SG components complex shown in F. (D) Classes of UBQLN2 interactors grouped by domain structure. (E) STRING network of UBQLN2 interactors found in the G3BP-dependent SG proteome (56). Dotted and solid lines represent low confidence and high confidence connections, respectively. Members represented in the four clusters include Uchl1, molecular chaperones (II), translation factors (III), and RNA trafficking proteins (IV). We focused further work on the class I hnrN FUS.

**Results**

**UBQLN2 Associates with SG Components.** To identify specific cellular functions for the UBQLN2 protein, we performed an unbiased quantitative proteomic screen for UBQLN2-interacting partners by stable isotope labeling with amino acids in cells (SILAC) coupled with nano-liquid chromatography tandem mass spectrometry (nLC-MS/MS) (50). Stable HEK293T cell lines with an integrated tetracycline-inducible FLAG-UBQLN2 construct were cultured with $^{15}$C$_2$N$_2$Arg and $^{15}$C$_2$N$_2$Lys heavy isotopes until complete labeling was attained. Proteins were extracted with Stil-like repeats that interact with the ATPase domain of Hsp70 (43, 44). All of the ALS-linked mutations map to this linker region, but its function in complex with the Ubx and Uba domains is unclear. Ubiquilin 2 (UBQLN2) is one of four human paralogs, also including UBQLN1, UBQLN4, and UBQLN3, but only UBQLN2 contains a unique, mammalian-specific PXX repeat region (45). Mutations in this repeat reportedly inhibit proteosomal degradation (33, 46). Expression of mutant UBQLN2 in Drosophila and rodent models leads to cognitive deficits and motor neuron degeneration (43, 47–49), but its specific mechanism of action is not well understood.

Here, we report a direct role for UBQLN2 in modulating RNP solubility during SG formation. While searching for UBQLN2-interacting proteins through quantitative proteomics, we found an enrichment of SG components. In cells, UBQLN2 not only resides in SGs but also acts as a negative regulator of SG assembly. Mechanistically, UBQLN2 increased the fluidity of ALS-linked mutant FUS–RNA complexes, leading to an increase in the dispersion of FUS liquid droplets and suppression of FUS-seeded SGs. ALS-linked mutations impaired the function of UBQLN2 in regulating RNP dynamics and SG formation. Together, these results reveal a previously unrecognized role for UBQLN2 in directly modulating the early-stage dynamics of LLPS and SG formation associated with the RBP FUS.
CHAPSO lysis buffer, coimmunoprecipitated with FLAG-UBQLN2 on anti-FLAG (M2) beads, and eluted with FLAG peptide. Identically processed lysate from \(^{12}\text{C}_6^{14}\text{N}_4\) Arg and \(^{12}\text{C}_6^{15}\text{N}_2\) Lys light-labeled HEK293T cells treated with doxycycline was used as a control. Eluants were pooled and separated by SDS/PAGE, and peptides were digested and extracted for LC-MS/MS analysis (Fig. 1A and B).

From this proteomic analysis, we identified 181 putative interactors for UBQLN2 enriched over 1.5-fold, 13 of which were enriched more than 10-fold (Fig. 1C and Dataset S1). These interactors could be subclassified by domain structure into four groups: molecular chaperones, AAA ATPases (ATPases associated with diverse cellular activities), RNA/DNA binding proteins, and transmembrane proteins (vesicle trafficking, ER/Golgi/lysosomal membrane, and mitochondrial membrane proteins) (Fig. 1D). Included in this list were previously identified UBQLN2 interactors: Hsp70 molecular chaperones HSPA1A, HSPA8, and HSPA13/Stch; ERAD chaperones FAF2/UBXD8 and HERPUD1; AAA ATPase VCP; proteasome cap subunits; RBPs hnRNPU and hnRNPA3; and membrane proteins ESyt2 and INSR (39, 42–44, 51–54) (Dataset S1). Western blot validation of some of the most enriched interactors confirmed our peptide search results from the LC-MS/MS analysis (SI Appendix, Fig. S1).

During the course of our analysis of UBQLN2 interactors, we noticed that members of every group except the membrane proteins were also represented in the SG proteome (55–58). To identify functional classes of proteins in SGs that UBQLN2 binds, we mapped the connectivity of SG-associated UBQLN2 interactors via STRING (Search Tool for the Retrieval of Interacting Genes/Proteins) network analysis (59). Four major classes of proteins emerged from this analysis: (i) hnRNPs, (ii) molecular chaperones, (iii) translation factors, and (iv) RNA trafficking proteins (Fig. 1E). The majority of ATP-dependent molecular chaperone assemblies found in the G3BP-dependent SG proteome (56), including VCP/p97, minichromosome maintenance protein complex (MCM), RuvB, and TriC (56), were represented in our SILAC analysis (groups II and IV). The karyopherins, A2 and B1, a class of proteins recently identified to solubilize hnRNPs fibrils (60–63), were also represented in group IV. Notably, however, a subclass of ALS-linked hnRNPs known as the FET family, including FUS, EWS, and TAF15 (64), were also identified (group I). Among RBPs, FUS showed the highest peak intensity among the hnRNPs (Dataset S1). Overall, the results of this proteomic analysis indicated that UBQLN2 associates with SG components in the absence of stress.
UBQLN2 Associates with SGs. To determine if UBQLN2 associates with SG components at SGs, we examined cells by immunofluorescence staining with UBQLN2-specific antibodies (SI Appendix, Fig. S2) under stress conditions. In response to acute sodium arsenite stress (0.5 mM for 30 min), endogenous UBQLN2 formed cytoplasmic puncta that colocalize with the core SG components G3BP and TIA-1 in HeLa cells (Fig. 2A, Middle row and Fig. 2C, second row). Depleting UBQLN2 with a specific shRNA (Fig. 2B and SI Appendix, Fig. S2) eliminated the UBQLN2 signal in G3BP-containing SGs, confirming that the UBQLN2 signal in SGs is specific (Fig. 2C, Bottom row and Fig. 2C and SI Appendix, Fig. S6, Bottom row).

Visualization of UBQLN2 in SGs was enhanced by use of an unconventional SG staining technique. We found that simultaneously fixing and permeabilizing cells with paraformaldehyde and Triton X-100 effectively limited the background cytoplasmic signal (11), but its localization under stress conditions (58, 69), we next tested if UBQLN2 localizes to SGs. UBQLN2 invariably localized to SGs (Fig. 2D and SI Appendix, Fig. S7). Some SG components are also de-
To predict if annotated low-complexity regions in UBQLN2 are functionally relevant to its localization to SGs, we first performed bioinformatic analysis of this region. Like Amino Acid Composition (PlAAC) revealed that UBQLN2 contains several low-complexity regions annotated by the SMART (Simple Modular Architecture Research Tool) algorithm (70). Analysis of the full-length protein via PlAAC (Prion-Like Amino Acid Composition) software revealed that UBQLN2 contains two putative prion-like domains (PrDs), a type of low-complexity domain that can mediate protein self-association (71), within this linker (Fig. 3A). The first region is located just downstream of the Ubl domain before the first set of Sti1-like repeats. The second region includes a second set of Sti1-like repeats specific to higher eukaryotes (44). This second region is the same one recently found to be essential for UBQLN2 oligomerization (72). The liquid droplet theory of SG formation predicts that low-complexity flexible regions in SG proteins can oligomerize to drive the phase separation of these proteins with RNA into granules. Based on this observation, we predicted that the Sti1-like linker would be sufficient to drive UBQLN2 into SGs.

To test if the Sti1-linker of UBQLN2 is sufficient to drive it into SGs, we constructed a new regulatable FLAG-UBQLN2 Flp-In HeLa cell line that would be ideal for imaging. This cell line inducibly expresses UBQLN2 at near-endogeneous levels when treated with a low level of tetracycline (1 μg/mL). The full-length FLAG-UBQLN2, but not FLAG-GFP, colocalized with the SG marker TIA-1 after 30 min of heat stress, indicating that the FLAG tag itself does not drive protein localization to SGs. The expression of the FLAG-tagged Sti1-linker in the Flp-In system was relatively low, but it colocalized with SGs, indicating that the linker region is sufficient for UBQLN2 localization to SGs (Fig. 3B and C).

**UBQLN2 Negatively Regulates SG Formation.** Overexpression of core SG components that contain low-complexity domains, such as TIA-1, G3BP, FUS and TDP-43, alone can drive SG formation (15, 22, 73–75). To test if UBQLN2 could seed SG formation, we overexpressed FLAG-tagged UBQLN2 in transiently transfected HeLa cells (Fig. 4B) and stained for the SG marker TIA-1. In no case did overexpressing UBQLN2 alone drive SG formation (Fig. 4A, second column and C). Instead, overexpressing UBQLN2 had the effect of suppressing SG formation. The percentage of

![Image](cell-biology.png)
cells with large SGs was significantly decreased at all time points during heat stress in the presence of elevated levels of UBQLN2 (Fig. 4C). The ALS-linked mutant P497H or P506T partially interfered with UBQLN2’s ability to suppress SG formation (Fig. 4A, third and fourth columns and C) despite being overexpressed at the same level as the wild-type protein (Fig. 4B). This partial failure indicates that these missense mutations impair UBQLN2’s function by disrupting large SG formation.

Next, we asked if depleting endogenous UBQLN2 would affect SG formation. Ninety-six hours after transfection with UBQLN2-specific shRNAs, HeLa cells were exposed to heat stress. The depletion of UBQLN2 resulted in a nearly twofold increase in the percentage of cells with large SGs, beginning at 30 min (Fig. 4D and F). As the percentage of cells with SGs increased to nearly 100% at 2 h, UBQLN2 levels no longer affected the percentage of cells with large SGs, indicating that SGs enlarge faster when UBQLN2 levels are decreased (Fig. 4F). Even among the cells treated with UBQLN2 shRNA, those with higher levels of UBQLN2 expression showed a significantly lower level of large SGs (SI Appendix, Fig. S10), supporting this finding. This increase in the percentage of cells with large SGs corresponded to a significant increase in SG cross-sectional area and an increase in the number of all SGs per cell at time points before 2 h of heat stress (SI Appendix, Fig. S11). The change in the percentage of cells with large SGs upon UBQLN2 depletion could not be explained by an increase in the levels of the core stress component G3BP or TIA-1 protein (SI Appendix, Fig. S12), suggesting that depletion of UBQLN2 led to a concentration of SG components in larger SGs. Together, these data indicate that UBQLN2 negatively regulates SG size.

**UBQLN2 Forms a Complex with FUS and Suppresses Its Recruitment to SGs.** Based on the localization and negative regulatory function of UBQLN2 at SGs, we reasoned that UBQLN2 may physically interfere with the process of SG formation. To investigate UBQLN2’s role in SG formation, we focused on its interaction with the highest ranked hnRNP in our SILAC analysis, FUS, which also has a well-established link to ALS pathology. FUS is an RBP that contains an amino-terminal, low-complexity, QGSY-rich, and Gly-rich region responsible for its oligomerization and phase separation into SGs. To confirm the interaction between UBQLN2 and FUS detected in our SILAC analysis (Fig. 1 and Dataset S1), we performed coimmunoprecipitation experiments with FLAG-tagged UBQLN2 and V5-tagged FUS. FUS immunoprecipitated with FLAG-tagged UBQLN2, but not with FLAG-tagged GUS control protein (Fig. 5A). The introduction of an ALS-linked UBQLN2 mutation, P497H or P506T, significantly decreased the interaction between UBQLN2 and FUS despite similar FUS protein expression level (Fig. 5A and B).

We then tested if UBQLN2 regulates the recruitment of FUS to SGs. We first developed a system in HeLa cells to monitor SG formation with a FUS-GFP construct that spontaneously forms SGs in a small percentage of cells in the absence of stress. We designed this construct with a long C-terminal linker (13 aa) between FUS and GFP to limit GFP interference with the FUS QGSY-rich/Gly-rich intrinsically disordered region. UBQLN2 was cotransfected with FUS-GFP, and its effects on SG formation were monitored. Under heat stress, FUS-GFP-positive SGs robustly formed in cells with endogenous UBQLN2 levels (Fig. 5C). However, in cells in which UBQLN2 levels were elevated, there were significantly fewer large SGs present (Fig. 5C and D), indicating that UBQLN2 interfered with FUS-GFP recruitment to SGs. These data are consistent with the observation that UBQLN2 negatively regulates SG formation.

Next, we asked if UBQLN2 affects the formation of FUS–RNA complexes in an electromobility shift assay (EMSA). Monomer FUS formed a discreet complex with polyuridine-50 (pU50) RNA (Fig. 5E). Increasing the FUS protein concentration from 5 nM to 500 nM caused the probe signal to shift to a higher molecular weight position corresponding to FUS multimer. We then added native purified UBQLN2 protein to test the effect of UBQLN2 on FUS–RNA complex formation. At a 500 nM concentration of FUS, UBQLN2 supershifted the FUS–RNA complex. This result indicates that UBQLN2 can form a stable complex with FUS multimer in the presence of RNA. Furthermore, increasing concentrations of UBQLN2 protein freed RNA from the FUS–RNA monomer complex and RNA bound to FUS monomer from the FUS multimer complex (Fig. 5E). These data suggest that UBQLN2 can influence the formation of FUS–RNA complexes.

**UBQLN2 Promotes ALS-Linked FUS–RNA Complex Dynamics.** Next, we asked if UBQLN2 could affect the dynamics of FUS–RNA complexes. Based on our observation that UBQLN2 freed RNA from the FUS–RNA monomer complex and FUS–RNA monomer from the FUS–RNA multimer complex, we expected that UBQLN2 would decrease the stability of FUS–RNA complexes formed. To test this hypothesis, we employed a single-molecule Förster resonance energy transfer (smFRET) assay to measure the dynamics of FUS–RNA complex assembly using a FUS mutant (R244C) with a nearly static interaction with RNA. The
conformation of a Cy3-Cy5-labeled RNA was measured by smFRET using a total internal reflection fluorescence (TIRF) microscope (100-ms resolution). Addition of RBP to the RNA changes the distance between the Cy3 and Cy5 tags reflected by the FRET ratio and alters the stability of the RNA conformation reflected by the FRET fluctuation. We expected that addition of UBQLN2 protein would increase the static interaction of FUSR244C with RNA (76). In the absence of the RBP FUS, the RNA probe exhibited a steady low FRET signal due to the Cy3-Cy5 dye separation by pU50 (Fig. 6 B and C, panel 1). Addition of FUSR244C resulted in a nearly static Cy3-Cy5 FRET signal regardless of FUS mutant concentration. The addition of FUSR244C at a high concentration (1 μM) resulted in a highly static FUS–RNA interaction (Fig. 6 B and C, panel 3) in greater than 85% of molecules (Fig. 6D, 0 min). Addition of wild-type UBQLN2 to this complex consistently shifted its dynamics from static to dynamic. Within 5 min of UBQLN2 addition, the proportion of dynamic molecules increased from 18% to 55% (Fig. 6D). After 40 min, nearly 65% of molecules were classified as dynamic (Fig. 6D). However, not only did the number of dynamic molecules increase but also the frequency of the FRET fluctuation among those dynamic molecules. Analysis of 300 time intervals between FRET peaks from over 100 single molecules revealed that between 5 and 20 min, the time constant (τ) for the exponential decay fit decreased from ~10 s down to 1 s (Fig. 6E). This change in dynamics indicates that UBQLN2 is able to increase the dynamics of FUS mutant interaction with RNA over time.

The FUS-bound RNA FRET ratio reflecting the conformation of the complex was also altered by addition of UBQLN2. At a high FUS concentration (1 μM), two populations of high and intermediate FRET signal molecules exist. The intermediate FRET signal represents RNA bound to soluble multimerized FUS, whereas the high FRET signal represents RNA bound to higher order insoluble FUS. Addition of UBQLN2 to this complex led to a decrease in the intermediate FRET signal between 5 and 20 min (Fig. 6C, panels 3–6) on the same time scale that we saw an increase in FUS dynamics. As we observed for wild-type FUS (Fig. 5E), this shift indicates that UBQLN2 dissociates soluble FUS–RNA complexes. UBQLN2 was unable to alter the insoluble FUS–RNA complex composition. These data are consistent with the conclusion that UBQLN2 alters the dynamics of FUS–RNA complex formation. Furthermore, in contrast to wild-type UBQLN2, P497H and P506T mutant UBQLN2 failed to restore FUSR244C dynamics, with only 10% and 30% of molecules showing dynamic smFRET signals, respectively (Fig. 6 B, panels 7 and 8 and D). This failure to affect FUS–RNA complex assembly dynamics indicates a partial compromise of UBQLN2 function conferred by these ALS-linked mutations.

### UBQLN2 Suppresses FUS–RNA LLPS.

The dynamics of R–RNA complex formation directly impact the LLPS of RBPs into liquid droplets (76). The dynamic interaction of wild-type FUS with RNA leads to the formation of smaller liquid droplets. In contrast, the static interaction of FUSR244C with RNA leads to the formation of large liquid droplets. Based on the finding that UBQLN2 increased FUS–RNA complex dynamics, we hypothesized that UBQLN2 addition would result in a decrease in FUS residence time in phase-separated droplets, and thus decrease the effective size of those droplets. To follow UBQLN2 activity, we performed a FUS liquid droplet assay by mixing FUSR244C protein with partially Cy3-labeled polyuridine 40 (pU40) RNAs with or without UBQLN2. Tobacco etch virus (TEV) protease was added to cleave off the maltose-binding protein (MBP) solubility tag from FUS to trigger the formation of liquid droplets, and fluorescent images were taken at regular time intervals after protease digestion to monitor the size and number of the droplets. Within a period of 20 h, FUSR244C–RNA droplets formed and increased in both size and number. When UBQLN2 was present, the FUSR244C–RNA droplets formed were smaller in size but more numerous compared with those formed in the absence of UBQLN2 (Fig. 7 A and B, quantitated in Fig. 7 C and D). Notably, the FUSR244C–RNA droplets in the absence of UBQLN2

![Figure 6](https://example.com/f6.png)

**Fig. 6.** UBQLN2 decreases FUSR244C–RNA interaction dynamics. (A) pU40 probe design and sample static and dynamic single-molecule traces showing the dwell time constant (τ). (B) Representative traces showing the fluctuation of the FRET ratio for single molecules over time (panels 1–8). FUS-m, FUS mutant FUSR244C; RNA only (cyan; panels 1–3), FUS-m mixed with pU40 RNA (red; panels 1–3), FUS-m mixed with pU40 in the presence of wild-type UBQLN2 (cyan; panels 4–6), and mutant UBQLN2 P497H and P506T (cyan; panels 7 and 8). The gray arrows point to the FRET peak broadened and flattened by UBQLN2 addition. (C) Percentage of single molecules with dynamic vs. static smFRET ratios. More than 1,000 traces were surveyed for this analysis. UBQLN2 mutant traces were collected between 20 and 40 min. Wild-type UBQLN2 addition alters FUSR244C–RNA complex dynamics, while mutant UBQLN2 does so to a lesser extent. (E) τ of FRET fluctuation taken at 5, 20, and 40 min after addition of wild-type UBQLN2 to FUSR244C. At 5–20 min after UBQLN2 addition, the FRET fluctuation rate dramatically increases for single molecules that are dynamic.

Alexander et al.
Fig. 7. UBQLN2 suppresses mutant FUS recruitment into phase-separated droplets. (A) Phase-separated droplets of FUS\textsuperscript{R244C} mutants formed over 20 h. (B) Droplets of FUS\textsuperscript{R244C} with UBQLN2 formed over 20 h. (C) Area of droplets taken over 20 h. Red and light blue indicate FUS\textsuperscript{R244C} without and with UBQLN2 added, respectively. UBQLN2 addition leads to an increase in average liquid droplet area. (D) Number of droplets per imaging area. UBQLN2 addition leads to a decrease in liquid droplet number. (E) Circularity of droplets over 20 h. UBQLN2 addition leads to maintenance of liquid droplet circularity. More than 400 droplets in three to four fields of view were used for this analysis. All error bars shown are SEM. The experiment was repeated twice.

displayed nonspherical, irregular patterns, whereas those in the presence of UBQLN2 remained highly spherical over the entire time course. These nonspherical irregular droplets may represent the transition from the reversible liquid-like, phase-separated state of FUS to a more stable, solid state of FUS. Taken together, these results suggest that UBQLN2 is able to prevent the liquid-to-solid transition of FUS by increasing the FUS–RNA complex formation dynamics that underlie FUS phase separation. This activity is consistent with the negative regulatory role that UBQLN2 plays in SG formation.

Discussion

In this study, we demonstrate a previously unknown role for UBQLN2 in regulating SG formation. UBQLN2 directly acts to promote the dynamics of FUS–RNA complexes and decrease the effective rate of FUS phase separation into liquid droplets, thereby suppressing SG formation. Mutations in UBQLN2 impair binding to FUS, resulting in loss of its ability to regulate the dynamics of FUS–RNA complexes and SG formation. These results expand the known functions of UBQLN2 and provide a direct link between protein and RNA homeostasis in normal stress responses and the pathogenesis of ALS/FTD.

These findings reveal a function of UBQLN2 independent of its previously established roles in mediating protein clearance. Instead of engaging with the protein degradation system via its Uba and Ubl domains, UBQLN2 associates with SG components through its Sti1-like linker region and influences the early process of molecular complex dynamics in phase separation that drives SG formation. Our quantitative proteomic analysis shows that UBQLN2 associates with SG components under homeostatic conditions, suggesting that these interactions exist before SG formation and UBQLN2 acts to regulate the exchange of these components into and out of SGs. Our time course analysis of SGs demonstrates that UBQLN2 is not a stable component of SGs but that its presence at the initial phases of SG assembly delays SG initiation, resulting in negative regulation of SG size. Notably, UBQLN2 does not appear to regulate the levels of core SG components but rather modulates the state of the components to be recruited. One of the main groups identified as UBQLN2-interacting SG components is the hnRNPs, consistent with previous reports that UBQLN2 interacts with hnRNPA1, hnRNPA3, and hnRNPU (52). We have focused on the hnRNP FUS, which contains a low-complexity region common among these hnRNPs, as a previously unknown interactor of UBQLN2 in our further analysis. This function is similar to the chaperone function of UBQLN2 in maintaining the solubility of transmembrane mitochondrial precursor proteins (40), but distinct in that it involves the modulation of protein–RNA interaction dynamics instead of its regulation of protein clearance.

We demonstrate that UBQLN2 has a direct function in promoting the dynamics of FUS–RNA complexes and suppressing the growth of FUS liquid droplets and their transition into more stable and solid states, which is consistent with the role of UBQLN2 in negatively regulating SG formation. This function is most reminiscent of the recently described role of ATP as a biological hydrotrope (77). Also, like the recently described nucleocytoplasmic transport protein transportin 1/karyopherin \( \beta 2 \), UBQLN2 phase-separates itself, which has been attributed to the second set of Sti1-like repeats in UBQLN2 (72). Interestingly, UBQLN2 itself does not drive SG formation like other proteins with PrDs, but rather antagonizes the recruitment of SG components to SGs. These observations represent a potentially unrecognized mode of action for low-complexity domain proteins in SG formation. Previously described SG regulation has focused on regulation of levels of individual SG components, posttranslational modifications of SG components, and SG disaggregation through PQC mechanisms (29–32, 55, 56, 78, 79). Our proteomic analysis shows that UBQLN2 associates with many of the PQC factors, including ubiquitin, Hsp70, VCP, and Tric (Dataset S1), suggesting that UBQLN2 may cooperate with other PQC factors in SG regulation. However, in a mechanism that is not mutually exclusive, our present study demonstrates a distinct way that UBQLN2 directly regulates the dynamics of protein–RNA complexes in the early stages of SG formation (SI Appendix, Fig. S15). Although we chose to focus on FUS as a
previously characterized RBP recruited to SGs via its low-complexity domain and linked to ALS/FTD (15), we speculate that the solubility of other RBPs isolated in our proteomic screen that bind RNA and phase-separate into SGs could also be regulated by UBQLN2. Together, these findings expand our understanding of the different modes of SG regulation.

The results indicating that ALS/FTD-linked mutations in UBQLN2 (P497H and P506T) dampen UBQLN2’s association with FUS, and thus impair the ability of UBQLN2 to regulate FUS–RNA interaction dynamics and SG formation, suggest that these processes may underlie the pathogenesis of ALS/FTD. FUS is one of a number of hnRNPAs, including EWS, hnRNPA1, and hnRNPA2/B1, associated with ALS/FTD that we isolated in our proteomic screen that contain low-complexity flexible regions imparting the ability to phase-separate, but also to aggregate. Mutations in these hnRNPs have been reported to increase their propensity to collect in SGs, disrupting SG function as an adaptive stress response (13, 15, 27). Increased residence of hnRNPs in SGs may thus be directly linked to formation of abnormal SGs prone to form the pathological inclusions found in patients with ALS/FTD. We have shown that relative levels of UBQLN2 to SG components directly impact the rate of growth of large cytoplasmic SGs. Because ALS-linked mutations in UBQLN2 impair its interaction with hnRNPs or its function in maintaining hnRNP–RNA complex fluidity, the mutations could compromise the intrinsic ability of UBQLN2 to protect against aberrant SG formation and subsequent disease pathology.

This protective effect is consistent with previous reports that increasing the expression of UBQLN2 or its family members protects against the toxicity of a variety of neurodegeneration-related proteins, including amyloid-β, polyglutamine repeats, and TDP-43 (80–82). Collectively, the present study results reveal that UBQLN2 directly regulates the early stages of SG formation and suggest that it has a critical cytoprotective role at the junction between protein and RNA homeostasis, both of which underlie neurodegenerative diseases.

Materials and Methods

Antibodies for Western Blotting and Immunocytochemistry. Rabbit anti-UBQLN2 (HPA0006431; Sigma) and mouse anti-UBQLN2 (NB2; Novus) antibodies were used in conjunction to detect UBQLN2 via immunocytochemistry and Western blot (SI Appendix, Fig. S2). Goat anti–TIA-1 (C-20; Santa Cruz Biotechnology) and mouse anti–G3BP (611216; BD Biosciences) were used to detect SGs, and goat anti-4E–T (N-18; Santa Cruz Biotechnology) was used to detect P-bodies.

Protein Purification. His-GFP-TEV-UBQLN2 and His-FUS for the smFRET experiments were purified by nickel-nitritotriacetic acid (NTA) affinity chromatography from Escherichia coli, followed by size exclusion chromatography (SI Appendix, Fig. S14). GST-FUS and GST-FUS444C for the EMSA and MBP-TEV-FUS for the droplet assay were purified as described by Zhang et al. (83) and Burke et al. (84), respectively.

Immunoprecipitation. For the SILAC analysis, 3x-FLAG-UBQLN2 was immunoprecipitated on FLAG beads and eluted with FLAG peptide in a 0.3% CHAPSO buffer [50 mM Hepes (pH 7.9), 150 mM NaCl, 2 mM EDTA] at 4 °C. SILAC LC-MS/MS analysis was performed as reported by Ong et al. (50). To validate the UBQLN2–FUS interaction, 3x-FLAG-UBQLN2 and FUS-V5 were coimmunoprecipitated in 1% Nonidet P-40 and 0.05% deoxycholate buffer [50 mM Tris·HCl (pH 7.5), 150 mM NaCl, 0.4 mM EDTA] on protein A magnetic beads prequillified with anti-FLAG (M2) antibody (F3165; Sigma). Beads were washed five times with lysis buffer and bound protein was eluted with low pH buffer (21208; Pierce) into 1 M Tris (pH 8.0) buffer.

EMSA. Samples were prepared by mixing 0.5–1 nM Cy3-Cy5 dual-labeled RNA probe (used in smFRET experiments) with varying concentrations of proteins in binding buffer [50 mM Tris·HCl (pH 7.5), 150 mM KCl, 2 mM MgCl2, 100 mM β-mercaptoethanol, 0.1 mg/mL BSA]. Samples were mixed with loading dye and run on a 6% DNA retardation polyacrylamide gel (Invitrogen). RNA mobility was visualized using a Typhoon scanner in fluorescent mode.

smFRET via TIRF Microscopy. Single-molecule imaging was performed as previously described by Zhang et al. (83).

Liquid Droplet Assay. One micromolar MBP-FUS, 1 μM unlabeled 40-nt-long pUrev, 4 μM UBQLN2, and 10 nM Cy3-labeled pUrev were prepared in 50 mM Tris·HCl (pH 7.4), 100 mM NaCl, 1 mM EDTA, and 1 mM DTT buffer. TEV protease was added to cleave the MBP tag off of FUS. To visualize droplets, this mixture was added to the surface of an eight-well chambered cover glass (Nunc Lab-Tek) and imaged using a Nikon Ti Eclipse microscope equipped with a 100x oil-immersive objective, 555 nm laser, Cy3 emission filter, and EM CCD Andor camera in a 133-μm² field. We used intensity thresholding to mask and quantify the number and shape of the droplets in ImageJ (NIH).

Statistical Analysis. All graphs were prepared and data were analyzed in GraphPad Prism, except where noted. Column data were analyzed by a standard one-way ANOVA with Dunnett’s method for correction for multiple pairwise comparisons. Group data were analyzed via a Student’s two-tailed ANOVA with Sidak’s correction method for multiple comparisons. Standard cell biology techniques for cell culture, transfection, immunoblotting, and SDS/PAGE separation and immunofluorescence microscopy were employed. Fixed cells were imaged on a Leica SP8 confocal microscope. Brightness and contrast adjustment, colocalization, SG size distribution, and percentage of cells with SGs analyses were performed in ImageJ. Prion-like α-synuclein acid analysis was performed using the Massachusetts Institute of Technology resource (plaac.wi.mit.edu, accessed September 6, 2017).

ACKNOWLEDGMENTS. We thank Han-Xiang Deng for UBQLN2 cDNA with P497H and P506T mutations, Andrew Holland for the Flp-In HEK cell line, Yihong Ye for the BAG6 antibody, and other J.W. laboratory members for helpful discussions. This work was supported by grants from the NIH (NS074324 and NS089616), Robert Packard Center for ALS Research at Johns Hopkins, Muscular Dystrophy Association, and ALS Association (to J.W.). E.J.A. was supported by an NIH Training Grant (T32CA009110).


51. Kim TY, Kim E, Yoon SK, Yoon JB (2008) Herp enhances ER-associated protein deg-